Stem Cell Differentiation Composition for Insulin Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for differentiating stem cells into insulin-producing cells are time-consuming, expensive, and pose safety concerns, limiting their effectiveness in treating diabetes mellitus.

Innovation Solution

A composition comprising putrescine, glucosamine, and/or nicotinamide is used to induce differentiation of stem cells into insulin-producing cells within a short period, enhancing insulin secretory function and reducing the time required for differentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional multi-stage differentiation protocols are used, then differentiation into insulin-producing cells can be achieved, but the process requires several weeks and is expensive

Engineering Contradiction:

Improvedifferentiation efficiencyVSAvoiddifferentiation time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent changes the chemical parameters of the differentiation medium by incorporating specific concentrations of putrescine (1-20 μM), glucosamine (10-100 μM), and nicotinamide (10-100 μM) to accelerate the differentiation process from several weeks to a shorter duration while maintaining efficiency

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses a composite differentiation medium containing multiple chemical agents (putrescine, glucosamine, and nicotinamide) working synergistically to achieve efficient differentiation in reduced time, combining the effects of polyamines, amino sugars, and nicotinamide derivatives

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional differentiation protocols are used, then insulin-producing cells can be generated, but the cost is high due to multiple stages and expensive reagents

Engineering Contradiction:

Improvedifferentiation efficiencyVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent simplifies the differentiation protocol by changing the medium composition parameters to include affordable chemical agents at optimized concentrations, reducing the need for multiple expensive stages while maintaining high differentiation efficiency

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs relatively inexpensive chemical compounds (putrescine, glucosamine, nicotinamide) that can be readily obtained and used in standardized protocols, replacing expensive proprietary reagents and multi-stage procedures

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If stem cell transplantation is performed, then insulin deficiency can be treated, but safety concerns remain regarding current differentiation methods

Engineering Contradiction:

Improvetreatment efficacyVSAvoidsafety concerns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent optimizes the chemical parameters of the differentiation medium to achieve safe and efficient differentiation, using controlled concentrations of putrescine, glucosamine, and nicotinamide that promote proper cell development while minimizing safety risks

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230088644A1Composition for inducing differentiation into insulin-producing cells, and use thereof

Publication Date: 2023.03.23 SEOUL NAT UNIV HOSPITAL

AI summary

The present invention relates to a composition for inducing differentiation into insulin-producing cells, and a method for inducing differentiation into insulin-producing cells. By using a differentiation inducing composition according to an exemplary embodiment or a differentiation inducing method according to an exemplary embodiment, insulin-producing cells can be prepared in a short period by effectively inducing the differentiation of various types of stem cells into insulin-producing cells, and can be mass-produced in a relatively simple manner, and thus a pharmaceutical composition for preventing or treating diabetes mellitus, comprising insulin-producing cells and/or insulin produced thereby, can be provided.